RAP 0.00% 20.5¢ raptor resources limited

ResApp Fundamentals & General Discussion, page-77

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 301 Posts.
    lightbulb Created with Sketch. 539
    I ain't no doctor like awichiu so my analysis won't be as technical or in-depth as his.

    From quick research, it appears they have developed the next generation of respiratory imaging product which is meant to replace x-ray and CT since they are getting outdated. Compare to RAP, they're a more matured company (established in 2005) with FDA approval and reasonable amount of revenue and hence a much higher MC at the moment (IPO at $0.73 and SP now $1.73).

    Yes both are in the respiratory diagnostic market but it has a very different purpose compare to RAP's ResAppDx. The advantage of ResAppDx is about ease of use, affordable and being able to quickly diagnose a respiratory disease and also the ability to do the test remotely with a smartphone. Whereas 4DX is about providing further information & show a clearer image about the lungs where traditional x-ray & CT are unable to. Obviously this requires patient to present to the hospitals and doctors to carry out the scan.

    It's quite an interesting company. But IMO it wouldn't be a competitor of RAP's given the purpose of the two products are very different in nature.

    GLTAH and DYOR
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.